E. coli O104:H4 outbreak and haemolytic-uraemic syndrome

Medicina Intensiva

Volumn 36, Issue 8, 2012, Pages 576-583

  Borgatta, B ^a   Kmet Lunacek N ^b   Rello, J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

E. coli O104:H4; Haemolytic uraemic syndrome; Review; STEC O104

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFIXIME; CEFOTAXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DIURETIC AGENT; ECULIZUMAB; FOSFOMYCIN; GENTAMICIN; METRONIDAZOLE; MONOCLONAL ANTIBODY; PENICILLIN G; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROKITAMYCIN; ROXITHROMYCIN; SULFAMETHOXAZOLE; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BRAIN DISEASE; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE SEVERITY; ENTERITIS; ENTEROAGGREGATIVE ESCHERICHIA COLI; EPIDEMIC; HEMOLYTIC UREMIC SYNDROME; HUMAN; KIDNEY DISEASE; KIDNEY PERFUSION; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; NEPHROTOXICITY; PROGNOSIS; RENAL PROTECTION; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; SHORT SURVEY; SYSTEMATIC REVIEW;

DISEASE OUTBREAKS; ENTEROHEMORRHAGIC ESCHERICHIA COLI; HEMOLYTIC-UREMIC SYNDROME; HUMANS;

EID: 84859314425     PISSN: 02105691     EISSN: 15786749     Source Type: Journal    
DOI: 10.1016/j.medin.2011.11.022     Document Type: Short Survey

References (36)

1. European Center for Disease Control EU case definition: HUS caused by epidemic strain Shiga toxin 2-producing Escherichia coli 2011, [accessed 11.06.2011]. http://www.ecdc.europa.eu/en/healthtopics/escherichia_coli/epidemiological_data/Pages/EU_case_definition.aspx.
2. World Health Organization E. coli outbreak update 2011, [accessed 13.06.2011]. http://www.infectioncontroltoday.com/news/2011/06/who-issues-e-coli-outbreak-update.aspx.
3. European Center for Disease Control Shiga toxin producing E. coli (STEC): update on outbreak in EU 2011, [accessed 31.07.2011]. http://www.ecdc.europa.eu/en/activities/sciadvice/Lists/ECDC%20Reviews/ECDC_DispForm.aspx%3FList=512ff74f-77d4-4ad8-b6d6%20bf0f23083f30%26ID=1166%26RootFolder=%2Fen%2Factivities%2Fsciadvice%2FLists%2FECDC%20Reviews.
4. Rubino S., Cappuccinelli P., Kelvin D. Escherichia coli (STEC) serotype O104 outbreak causing haemolytic syndrome (HUS) in Germany and France. J Infect Dev Ctries 2011, 5:437-440.
5. Turner M. German E. coli outbreak caused by previously unknown strain. Nature 2011, 10.1038/news.2011.345.
6. Frank C., Werber D., Cramer J., Askar M., Faber M., Ander Heiden M., et al. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany - preliminary report. N Engl J Med 2011, 10.1056/nejmOA1106483.
7. Infection Control Today E. coli O104 investigation update 2011, [accessed 14.07.2011]. http://www.infectioncontroltoday.com/news/2011/06/e-coli-o104-investigation-update.aspx.
8. Tarr P., Gordon C., Chandler W. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005, 365:1073-1086.
9. Madappa P. E. coli infections. Medscape reference 2011, [accessed 14.07.2011]. http://emedicine.medscape.com/article/217485-overview%23a0104.
10. Bitzan M., Schaefer F., Reymond D. Treatment of typical (enteropathic) haemolytic uremic syndrome. Semin Thromb Hemost 2010, 36:594-610.
11. Trevathan E., Dooling E. Large thrombotic strokes in hemolytic-uremic syndrome. J Pediatr 1987, 102:402-404.
12. Niaudet P. Clinical manifestations and diagnosis of Shiga-like toxin associated typical haemolytic uremic syndrome in children. UpToDate 2011, [accessed 16.07.2011]. http://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-shiga-like-toxin-associated-typical-hemolytic-uremic-syndrome-in-children%3Fsource=search_result%26selectedTitle=1%7E150.
13. Schmidt S., Gaudinchet F., Meagher-Villemure K., Maeder P. Brain involvement in haemolytic-uraemic syndrome: MRI features of coagulative necrosis. Neuroradiology 2001, 43:581-585.
14. Fujii J., Kinoshita Y., Yutsudo T., Taniguchi H., Obrig T., Yoshida S.I. Toxicity of Shiga toxin 1 in the central nervous system of rabbits. Infect Immun 2001, 69:6545-6548.
15. Eriksson K., Boyd S., Tasker R. Acute neurology and neurophysiology of haemolytic-uraemic syndrome. Arch Dis Child 2001, 84:434-435.
16. Teramoto T., Fukao T., Hirayama K., Asano T., Aoki Y., Kondo N. Escherichia coli O-157-induced hemolytic uremic syndrome: usefulness of SCWP score for the prediction of neurological complication. Pediatr Int 2009, 51:107.
17. Theobald I., Kuwertz-Broking E., Schiborr M., Heindel W. Central nervous system involvement in haemolytic uremic syndrome (HUS) - a retrospective analysis of cerebral CT and MRI studies. Clin Nephrol 2001, 56:S3-S8.
18. Michael M., Elliott E., Ridley G., Hodson E., Craig J. Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. Cochrane Database Syst Rev 2009 Jan 21, (1):CD003595.
19. Safdar N., Said A., Gangnon R., Maki D. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. JAMA 2002, 288:996-1001.
20. Ikeda K., Ida O., Kimoto K., Takatorige T., Nakanishi N., Tatara K. Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection. Clin Nephrol 1999, 52:357-362.
21. Cimolai N., Carter J., Morrison B., Anderson J. Risk factors for the progression of Escherichia coli O157:H7 enteritis to hemolytic-uremic syndrome. J Pediatr 1990, 116:589-592.
22. Wong C., Jelacic S., Habeeb R., Watkins S., Tarr P. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000, 342:1930-1936.
23. Pavia A., Nichols C., Green D., Tauxe R., Mottice S., Greene K., et al. Hemolytic-uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations. J Pediatr 1990, 116:544-551.
24. Lynn R.M., O'Brien S.J., Taylor C.M., Adak G.K., Chart H., Cheasty T., et al. Childhood hemolytic uremic syndrome, United Kingdom and Ireland. Emerg Infect Dis 2005, 11:590-596.
25. Panos G.Z., Betsi G.I., Falagas M.E. Systematic review: are antibiotics detrimental or beneficial for the treatment of patients with Escherichia coli O157:H7 infection. Aliment Pharmacol Ther 2006, 24:731-742.
26. Martin D., MacDonald K., White K., Soler J., Osterholm M. The epidemiology and clinical aspects of the hemolytic uremic syndrome in Minnesota. N Engl J Med 1990, 323:1161-1167.
27. Higami S., Nishimoto K., Kawamura T., Tsuruhara T., Isshiki G., Ookita A. Retrospective analysis of the relationship between HUS incidence and antibiotics among patients with Escherichia coli O157 enterocolitis in the Sakai outbreak. Kansenshogaku Zasshi 1998, 72:266-272.
28. Shiomi M., Togawa M., Fujita K., Murata R. Effect of early oral fluoroquinolones in hemorrhagic colitis due to Escherichia coli O157:H7. Pediatr Int 1999, 41:228-232.
29. Slutsker L., Ries A., Maloney K., Wells J., Greene K., Griffin P. A nationwide case-control study of Escherichia coli O157:H7 infection in the United States. J Infect Dis 1998, 177:962-966.
30. Carter A., Borczyk A., Carlson J., Harvey B., Hockin J., Karmali M., et al. A severe outbreak of Escherichia coli O157:H7-associated hemorrhagic colitis in a nursing home. N Engl J Med 1987, 317:1496-1500.
31. Ostroff S., Kobayashi J., Lewis J. Infections with Escherichia coli O157:H7 in Washington State. The first year of statewide disease surveillance. JAMA 1989, 262:355-359.
32. Dundas S., Todd W., Stewart A., Murdoch P., Chaudhuri A., Hutchinson S. The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin Infect Dis 2001, 33:923.
33. McGannon C., Fuller C., Weiss A. Different classes of antibiotics differentially influence shiga toxin production. Antimicrob Agents Chemother 2010, 54:3790-3798. Epub.
34. Deutsche Gesellschaft für Infektiologie EHEC infection and antibiotic therapy 2011, [accessed 13.07.2011]. http://www.rki.de/EN/Home/homepage__node.html.
35. Lapeyraque A., Malina M., Fremeaux-Bacchi V., Boppel T., Kirschfink M., Oualha M., et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 2011, 364:2561-2563.
36. Garg A., Suri R., Barrowman N., Rehman F., Matsell D., Rosas-Arellano M., et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA 2003, 290:1360-1370.